OncLive | Idelalisib Improves Survival in High-Risk CLL OncLive Combination treatment with the PI3K-delta inhibitor idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), according to phase ... |
